BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

Two of China’s most prominent immuno-oncology companies made moves this week to bolster their CAR T cell therapy pipelines: one via a deal and the other with a financing. Innovent Biologics Inc. (HKSE:1801) has acquired...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
BioCentury | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32...
BioCentury | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
BioCentury | Apr 23, 2019
Translation in Brief

J&J and Boston University identify classifications to catch lung cancer

J&J and Boston University identified a subtype of precancerous lesions with genomic alterations and immune cell deficiencies that could be used to diagnose and stratify patients at the earliest stages of lung cancer. The findings,...
BioCentury | Nov 9, 2018
Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...
BioCentury | Nov 8, 2018
Product R&D

JLABS seeks lung cancer solutions in Shanghai

As Johnson & Johnson gears up to launch its Shanghai JLABS site early next year, the incubator’s head, Sharon Chan, has pegged lung cancer as one of the first priorities. Chan sees opportunity in China...
BioCentury | Nov 6, 2018
Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...
BioCentury | Oct 15, 2015
Company News

J&J partners with pair of Canadian companies

The Janssen Inc. unit of Johnson & Johnson (NYSE:JNJ) started separate collaborations with gene therapy company enGene Inc. (Montreal, Quebec) to treat inflammatory bowel disease (IBS) and oncology start-up Novera Therapeutics Inc. (Toronto, Ontario) to...
BioCentury | Jun 1, 2015
Company News

Turnstone Biologics cancer news

Turnstone Biologics launched to develop and commercialize oncolytic vaccine immunotherapies using its Marabex technology to treat cancer. The technology is in preclinical development. Founding partners of the newco include Fight Against Cancer Innovation Trust (Toronto,...
Items per page:
1 - 10 of 14
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

Two of China’s most prominent immuno-oncology companies made moves this week to bolster their CAR T cell therapy pipelines: one via a deal and the other with a financing. Innovent Biologics Inc. (HKSE:1801) has acquired...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
BioCentury | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32...
BioCentury | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
BioCentury | Apr 23, 2019
Translation in Brief

J&J and Boston University identify classifications to catch lung cancer

J&J and Boston University identified a subtype of precancerous lesions with genomic alterations and immune cell deficiencies that could be used to diagnose and stratify patients at the earliest stages of lung cancer. The findings,...
BioCentury | Nov 9, 2018
Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...
BioCentury | Nov 8, 2018
Product R&D

JLABS seeks lung cancer solutions in Shanghai

As Johnson & Johnson gears up to launch its Shanghai JLABS site early next year, the incubator’s head, Sharon Chan, has pegged lung cancer as one of the first priorities. Chan sees opportunity in China...
BioCentury | Nov 6, 2018
Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...
BioCentury | Oct 15, 2015
Company News

J&J partners with pair of Canadian companies

The Janssen Inc. unit of Johnson & Johnson (NYSE:JNJ) started separate collaborations with gene therapy company enGene Inc. (Montreal, Quebec) to treat inflammatory bowel disease (IBS) and oncology start-up Novera Therapeutics Inc. (Toronto, Ontario) to...
BioCentury | Jun 1, 2015
Company News

Turnstone Biologics cancer news

Turnstone Biologics launched to develop and commercialize oncolytic vaccine immunotherapies using its Marabex technology to treat cancer. The technology is in preclinical development. Founding partners of the newco include Fight Against Cancer Innovation Trust (Toronto,...
Items per page:
1 - 10 of 14